GLOW Peptide Blend: What's Actually Inside, and What the Evidence Shows

Research use only. GLOW and its component peptides are sold strictly for laboratory research. They are not FDA-approved, are not medicines or supplements, and nothing here is medical advice or a dosing protocol. "GLOW" is an informal name coined by the research-peptide market — not a studied drug, and not a combination any regulator has evaluated. Talk to a licensed professional before using any research compound.

Search "GLOW peptide" and you'll find it sold as a single miracle for skin, hair and recovery — usually next to a glossy before-and-after and a price. The first thing worth knowing is that GLOW isn't a peptide at all. It's a marketing name for a mixture of three separate peptides, and the exact recipe changes depending on who's selling it. This page is the un-glossy version: what's in the vial, how good the evidence is for each piece, and what results the science actually supports.

GLOW is a blend, not a molecule#

There is no compound called "GLOW" in the scientific literature. The name is a vendor coinage for a lyophilized (freeze-dried) blend built on three research peptides:

• GHK-Cu — a copper-binding tripeptide, the "skin and collagen" component.
• BPC-157 — a synthetic peptide studied for soft-tissue and gut repair.
• TB-500 — a synthetic fragment of thymosin β4, studied for cell migration and remodeling.

Because it's a blend, "GLOW" behaves more like a house recipe than a defined product. Two vials labeled GLOW from two different sellers can contain meaningfully different amounts of each peptide — which is exactly why you should never assume one vendor's write-up describes the vial you're actually holding. It also means every "GLOW benefit" you read is really a claim about GHK-Cu, BPC-157 or TB-500 individually. There is no study of GLOW as a combination — not in humans, not in animals. What follows is the evidence on the three parts, graded honestly.

If you're comparing GLOW to its close cousin KLOW (which adds a fourth peptide, KPV), that's a separate question with its own page — see GLOW vs KLOW: the KPV difference. This guide stays on GLOW itself.

What's inside — and why the ratios don't agree#

Here's the part vendor pages gloss over: "GLOW" doesn't pin down a recipe. A 70 mg vial is the common configuration, but it isn't the only one, and some sellers list smaller vials with a different split. Two splits you'll actually find for sale:

Same three peptides, two different products. The 50/10/10 mix is mostly GHK-Cu with a little repair support. The 27/5/10 mix is smaller, but relative to its GHK-Cu it carries almost twice as much TB-500. That difference isn't cosmetic — it changes what the vial is even for. One tracked vendor also sells a 90 mg vial labelled "70/10/10" without saying which peptide is the 70. So the single most useful thing you can do before buying is read the specific vial's Certificate of Analysis (COA) and confirm the per-peptide milligrams, rather than trusting the word "GLOW" on the label. A vendor that can't show you a per-batch COA can't actually tell you what's in the powder.

This ratio problem is also why "how do I dose GLOW?" has no clean answer — the answer depends entirely on which of the mixes above is in front of you. More on that below.

The three components, graded honestly#

For each peptide, here's the plain-English mechanism, an evidence grade, and where the ceiling of the research actually sits. The grades reflect human evidence specifically — a lot of this work is impressive in a petri dish or a mouse and untested in people.

GHK-Cu — the strongest of the three (and it's still mostly cosmetic)#

GHK-Cu is a naturally occurring copper tripeptide that declines with age. In lab work it stimulates the synthesis of collagen, elastin and glycosaminoglycans in dermal fibroblasts, supports those cells' function, and influences a broad set of genes tied to tissue remodeling and repair (Pickart & Margolina, 2018). This is the "glow" in GLOW — the collagen-signaling story is real and reasonably well characterized.

The honest caveat: most of the human-relevant evidence is topical and cosmetic — creams and serums for skin firmness and appearance — not injected-blend data. GHK-Cu is a genuine dermatology ingredient with a mechanistic and cosmetic track record, which is more than most peptides can say. It is not a proven injectable anti-aging therapy.

• Evidence grade: Moderate. Solid mechanism, real cosmetic/topical use, no rigorous trials of it as an injected research blend.

BPC-157 — promising in animals, barely tested in humans#

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. In preclinical models it shows striking regenerative and cytoprotective effects — accelerated healing of tendon, ligament, muscle, bone and nerve across many rodent studies. But a 2025 narrative review counted only three published human studies (a knee-injection study, a bladder study, and a two-person intravenous safety study) and concluded BPC-157 "should be considered investigational" and should not be recommended for clinical use until real human trials are done (McGuire et al., 2025). Our BPC-157 complete guide goes deeper on the specifics.

• Evidence grade: Preliminary. Robust animal data, human data "exceedingly sparse." Treat any recovery claim as extrapolation.

TB-500 — the most preclinical of the three#

TB-500 is a synthetic version of a region of thymosin β4, the main actin-sequestering peptide in mammalian cells. Thymosin β4 promotes cell migration, blood-vessel formation, cell survival and stem-cell maturation, which is the mechanistic basis for its wound-repair reputation (Philp & Kleinman, 2010). The catch, stated plainly in that review, is that this body of work is animal-model research — the foundation for clinical trials, not the outcome of them.

• Evidence grade: Preclinical. Interesting mechanism, essentially no controlled human data for TB-500 itself.

Put together: one component with a decent cosmetic track record (GHK-Cu), and two whose reputations rest almost entirely on animal work (BPC-157, TB-500). That's the real evidence profile behind the marketing.

Reported benefits vs. what's actually proven#

GLOW is marketed for a familiar cluster of outcomes. Here's the honest split between what's reported (anecdote, mechanism, marketing) and what's supported by evidence in humans.

The pattern is consistent: the skin claims are the best-grounded (thanks to GHK-Cu), the recovery claims are animal-stage, and the sweeping "rejuvenation" language has nothing behind it beyond the sum of three individual mechanisms. "Proven vs plausible" is the right lens for the whole category — most of GLOW's story lives in plausible.

GLOW "before and after": what results are realistic#

The GLOW search results are full of before-and-after photos. We're not going to add fake ones — we don't publish fabricated images, testimonials, or invented reviewer quotes, and any peptide site showing dramatic side-by-sides with no methodology deserves your skepticism. What we can do is describe what the mechanisms make plausible, and on what timeline.

If the underlying peptides do what the preclinical and cosmetic literature suggests, the most defensible expectation is gradual, skin-led change — the kind of thing GHK-Cu's collagen mechanism operates on, which unfolds over weeks to months, not days. Skin texture and appearance are where a real, visible effect is most plausible; connective-tissue recovery is a longer and far less certain story that rests on animal data.

A few honest counterweights:

• Photos are easy to stage. Lighting, hydration, angle, pump and time of day move "before/after" appearance more than most people think.
• A blend confounds everything. Even a genuine result can't be attributed to GLOW specifically — you can't separate it from diet, sleep, other actives, or regression to the mean.
• No blend trial exists, so there's no measured effect size, response rate, or timeline to point to. Anyone quoting one is inventing it.

The realistic summary: skin appearance is the outcome with the best mechanistic case, changes are gradual rather than dramatic, and everything past that is unproven for the blend. That's less exciting than the marketing — and it's the truth.

Safety, side effects and who should avoid it#

Because GLOW is three peptides at once, its risk profile is the union of all three. The blend has no human safety study, so this is component-level and precautionary.

• Copper load (GHK-Cu). GHK-Cu delivers copper. Anyone with a copper-metabolism disorder — Wilson's disease in particular — or copper sensitivity should avoid copper peptides entirely, and copper-peptide preparations can sting or irritate at higher concentrations.
• Angiogenesis / cell-growth caution (BPC-157, TB-500). Both peptides promote blood-vessel formation and cell proliferation in models. That's the point for repair, but the same activity is a theoretical concern for anyone with cancer or an active tumor, where you don't want to feed angiogenesis. Treat this as a genuine red flag, not a formality.
• Injection-site reactions are the most common practical issue with any reconstituted peptide — redness, swelling, tenderness.
• Anti-doping. Two of GLOW's three components are prohibited in tested sport: TB-500 (thymosin β4) and BPC-157, which a 2026 review notes is still on the WADA list (Yuan et al., 2026). Any athlete should check every component of a blend against the current WADA Prohibited List before going near it.
• Purity is not guaranteed. These are gray-market research chemicals. Actual content varies, and independent testing has caught peptides that were underdosed or off-spec. A per-batch COA is the minimum bar.
• Not FDA-approved, for anything. GLOW is a research blend, not a treatment. There is no approved human use, dose, or indication.

GLOW dosing reference: what the research shows, and the vial maths#

This section is a research reference, not a protocol. It sets out what published human data exists for each component, what's actually in the vials we track, and the arithmetic that links the two. None of it is a recommendation to use GLOW, and no regulator has approved any dose of the blend or its parts.

What the published research says about each component's dose#

No study has tested GLOW as a blend, so any "GLOW dosage" would have to be built from the individual peptides. For three of the four peptides sold in these blends, there is no published injected human dose to build it from.

A 2026 review of injectable peptides for orthopaedic surgeons, covering BPC-157, TB-500 and GHK-Cu, put it plainly: the indications, dosing, frequency and duration of treatment remain unknown (Mayfield et al., 2026). Schedules you see quoted for GLOW come from vendors and forums, not from research.

The commonly cited community reference amount#

Outside the research literature, community and vendor dosing guides for the standard 50/10/10 vial often cite 2.5 mg of GHK-Cu per draw. In that vial, it carries exactly 0.5 mg (500 mcg) each of BPC-157 and TB-500, because the split is 5:1:1. This is a reference amount, not a clinical dose. No trial has studied the blend, the figure comes from community and vendor guidance, and nothing here suggests anyone should use it.

Guides don't all agree on the number, or on what it measures:

• 2.5 mg of GHK-Cu with 500 mcg each of BPC-157 and TB-500: VialBase gives this as its starting amount, 10 units of a 70 mg vial mixed with 2 mL (VialBase). PeptideDeck gives the same amounts as a higher, recovery-focused tier, 15 units of a vial mixed with 3 mL (PeptideDeck).
• About 1.67 mg of GHK-Cu with 333 mcg each: 10 units of a 70 mg vial mixed with 3 mL, which is 2.33 mg of total blend. This is the daily amount in one stack guide (Peptide Dosing Protocols) and PeptideDeck's standard tier.
• "2,000 to 2,500 mcg of total blend": one guide states the amount as total blend, not GHK-Cu (PeptidesExplorer). In a 50/10/10 vial that is about 1.4 to 1.8 mg of GHK-Cu (the total × 50 ÷ 70).
• 2 mg of GHK-Cu with 400 mcg each of BPC-157 and TB-500, 2.8 mg of blend in all (Peptide Mind).

So "2.5 mg" is ambiguous. As GHK-Cu it is roughly 1.4 times the GHK-Cu in 2.5 mg of total blend (2.5 mg versus about 1.8 mg), and 1.5 times the 1.67 mg in the 10-units-at-3 mL figure. Check which a guide means before comparing numbers. The maths below uses 2.5 mg of GHK-Cu because it's a widely cited figure and it maps to round numbers in a 50/10/10 vial. It's a reference point for the arithmetic, not a recommendation.

What's actually in the vials we track#

There are six GLOW listings in our price tracker (September 2026):

• Two state 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500 in a 70 mg vial on their product pages: Peptide Partners and Regenerative Research.
• Peptide Supply Co. lists the same 50/10/10 in its product data (its store sits behind a sign-in), and its lab certificate is consistent with that split (see below).
• Two give only a 70 mg total: Crush Research and Blank Peptides.
• One, Peptime, sells a 90 mg vial labelled "70/10/10". The listing doesn't say which peptide is the 70.

So 50/10/10 is the split you can confirm, but it isn't the only one, and three listings don't fully say. Read your vial's label and COA before doing any maths.

Labelled mg and measured mg are also not the same thing. These Freedom Diagnostics certificates cover GLOW and its four-peptide sibling KLOW. Every one has a 50 mg GHK-Cu label and a 10 mg label for the thymosin component:

All figures are lot averages. Two things stand out. First, GHK-Cu, the component the maths below is anchored to, came in 18% to 28% over label on four of these six lots. Second, the thymosin component ranged from 7.98 mg to 12.13 mg, and the two Peptide Plugs lots two weeks apart read 12.13 mg and 9.08 mg. Even the name isn't consistent: the lab reports the same analyte as "TB-500" on one Peptide Plugs lot and "Thymosin Beta-4" on the next, so a certificate's label doesn't settle which molecule is in the vial.

The vial maths#

Once you add bacteriostatic water, every component's concentration is set at the same time. Two formulas cover it (ignoring the small volume the powder itself adds):

• Concentration (mg/mL) = component mg ÷ mL of water
• Syringe units on a U-100 insulin syringe (100 units = 1 mL) = (amount ÷ concentration) × 100

The tables below use a 70 mg GLOW vial split 50/10/10, anchored to GHK-Cu, the component with the most mass, at the 2.5 mg community reference amount described above. That is not a clinical dose. All figures assume the vial holds exactly what its label says, and the certificates above show it often doesn't.

We stop at 3 mL because at least two tracked vendors, Peptide Partners and Blank Peptides, give 3 mL as their GLOW vial's capacity.

Worked example, 70 mg GLOW (50/10/10) with 2 mL of BAC water:

1. GHK-Cu: 50 mg ÷ 2 mL = 25 mg/mL. BPC-157 and TB-500: 10 mg ÷ 2 mL = 5 mg/mL each.
2. Volume holding 2.5 mg of GHK-Cu: 2.5 ÷ 25 = 0.10 mL, which is 10 units.
3. What else is in those 10 units: 0.10 mL × 5 mg/mL = 0.5 mg BPC-157, and the same 0.5 mg TB-500.
4. Draws per vial: 50 mg of GHK-Cu ÷ 2.5 mg = 20. That's the same as 200 units in 2 mL ÷ 10 units per draw.

With 3 mL instead, the concentration drops to 16.67 mg/mL, so the same 2.5 mg of GHK-Cu takes 15 units (2.5 ÷ 16.67 = 0.15 mL). It still carries 0.5 mg each of BPC-157 and TB-500, and the vial still gives 20 draws. The water only changes the volume.

Those figures assume the label is exact. If the vial is like the lots above that measured about 59 to 64 mg of GHK-Cu, a draw calculated as "2.5 mg" really holds about 2.9 to 3.2 mg of GHK-Cu (for example, 2.5 × 64.17 ÷ 50 = 3.2).

The ratio never changes with water, but it does change with the split. At the same 2.5 mg of GHK-Cu, a 42 mg 27/5/10 vial carries about 0.46 mg of BPC-157 (2.5 × 5 ÷ 27) and 0.93 mg of TB-500 (2.5 × 10 ÷ 27). That's nearly twice the TB-500 of a 50/10/10 vial. For the 90 mg "70/10/10" vial, the ratio depends on which peptide is the 70, which the listing doesn't state.

To run your own vial's numbers, the calculator below opens a 70 mg GLOW vial with the 50/10/10 split; change the amounts to match your label or certificate. The step-by-step reconstitution guide covers mixing, sterile handling and storage.

Safety limits of blend dosing#

• You can't adjust one component on its own. The ratio is fixed at manufacture. A bigger draw to get more GHK-Cu gives you proportionally more BPC-157 and TB-500 (and KPV, in KLOW), and a smaller draw lowers all of them. Researchers who need to vary one peptide independently buy them separately.
• The human safety data is tiny. The BPC-157 pilots (12 women, and two adults on IV) reported no adverse events, but they were uncontrolled and very small (Lee et al., 2024; Lee & Burgess, 2025). A 2025 review concluded BPC-157 should be considered investigational (McGuire et al., 2025).
• The best-tolerated data is for a different molecule. In the thymosin β4 IV trial, adverse events were infrequent and mild to moderate, with no dose-limiting toxicity (Ruff et al., 2010). That was full-length thymosin β4 in a controlled setting, not TB-500 from a research vial.
• Growth-signal caution. β-thymosins are involved in tumour-cell migration and metastasis as well as normal repair (Sribenja et al., 2013). That's why an active or past cancer is a real red flag for this blend.
• Copper. Every draw delivers GHK-Cu's copper. Anyone with Wilson's disease or another copper-handling disorder should stay away from copper peptides.
• Label accuracy. In the certificates above, GHK-Cu ran up to 28% over label and the thymosin component ranged from 20% under to 21% over. Every component is a separate chance for the vial to differ from the maths.

Frequently asked questions

Where to buy GLOW#

Once you've decided GLOW is worth researching, the buying question — how cost per mg compares across vendors, which vendors publish COAs, and how the blend compares with buying the three peptides separately — has its own detailed breakdown: Buying GLOW peptide: cost per mg, vendors and COAs. For a quick look at live prices right now: